Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.
ratiopharm is a privately-held company owned by the Merckle Group, and based in Ulm, Germany. Founded in 1974, it now claims to be the leading generic company in Germany, and the third largest pharmaceutical company overall, in terms of prescriptions.
Sales in 2007 were 1,819 million euros, of which 819.4 million euros were in Germany, equal to around 45% of the total.
The company also has a major presence in other European countries, such as the UK and the Netherlands. ratiopharm has only a very limited presence in North America, although it has recently been expanding its Canadian operations.
ratiopharm has a generic biologic subsidiary named BioGeneriX. Founded in 2000, BioGeneriX has a number of alliances with potential biogeneric companies around the world. The most advanced project is for G-CSF, developed in collaboration with Neose. ? In February 2008, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions for two ratiopharm biosimilar medicinal products based on filgrastim.
In January 2009, ratiopharm’s founder died. The VEM Group, which owns ratiopharm, confirmed in early 2009 that the company would be put up for sale. In March 2010, the firm was acquired by Teva Pharmaceutical Industries, with the acquisition completing on 10th August 2010.
Table Of Contents
ratiopharm Generics Company Intelligence Report Table of Contents
Executive Summary 1 Introduction 2 ratiopharm acquired by Teva 2 ratiopharm international subsidiaries 2 BioGeneriX 3 Merckle Biotec 3 Merckle 3 PulmoTec 3 ratiopharm direct 3 Products 4 ratiopharm, ANDA Approvals January 2002 - September 2010 4 Recent Product Approvals 4 CHMP recommends approval of ratiopharm's generic Arava 4 CHMP adopts positive opinions for Ratioepo and Eporatio 4 Financial results5 ratiopharm Sales, in euros millions 5 ratiopharm Sales, in US$ millions 5 Major developments 6 Teva acquires ratiopharm 6 European Medicines Agency recommends recall of clopidogrel products 8 Litigation 9 ratiopharm Canada wins amlodipine patent challenge 9